Tait Davis Shanafelt
Medical Practice at 1 St, Rochester, MN
License number
Kentucky 46660
Issued Date
Dec 19, 2013
Expiration Date
Feb 28, 2018
Category
Hematology/Oncology
Type
Hospital Based
Address
Address
200 1St St SW, Rochester, MN 55905
Education
University of Colorado Denver School of Medicine, 1998
Phone
(507) 284-2511 (Work)
Professional information
Dr. Tait D Shanafelt, Rochester MN - MD (Doctor of Medicine)
Specialties:
Hematology, Medical Oncology, Oncology
Address:
Mayo Clinic
200 1St St SW, Rochester 55905
(507) 284-2511 (Phone)
200 1St St SW, Rochester 55905
(507) 284-2511 (Phone)
Certifications:
Hematology, 2005, Internal Medicine, 2001, Medical Oncology, 2004
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Mayo Clinic
200 1St St SW, Rochester 55905
Mayo Clinic Saint Marys Hospital
1216 2Nd St South #West, Rochester 55902
North Memorial Medical Center
3300 Oakdale Ave North, Robbinsdale 55422
200 1St St SW, Rochester 55905
Mayo Clinic Saint Marys Hospital
1216 2Nd St South #West, Rochester 55902
North Memorial Medical Center
3300 Oakdale Ave North, Robbinsdale 55422
Education:
Medical School
Co-Operative Medical College, Kochi, Kochi University
Graduated: 1998
Mayo Grad School Med/Mayo Fndn
University Of Wa School Of Med
Co-Operative Medical College, Kochi, Kochi University
Graduated: 1998
Mayo Grad School Med/Mayo Fndn
University Of Wa School Of Med
Tait Shanafelt, Rochester MN
Work:
Mayo Medical School
200 1St St Sw, Rochester, MN 55905
200 1St St Sw, Rochester, MN 55905
Methods Of Treating Hematologic Cancers
US Patent:
2012019, Jul 26, 2012
Filed:
Jul 27, 2010
Appl. No.:
13/388751
Inventors:
Neil E. Kay - St. Louis Park MN, US
Tait D. Shanafelt - Rochester MN, US
Tait D. Shanafelt - Rochester MN, US
Assignee:
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH - Rochester MN
International Classification:
A61K 31/7076, A61P 35/00, A61P 35/02, A61K 31/353
US Classification:
514 47, 514456
Abstract:
This disclosure relates to the treatment of hematologic cancers, for example, cancers of the blood, by methods that include administration of EGCG and at least one of a purine nucleoside analog and an alkylating agent. In particular, methods of treating chronic lymphocytic leukemia (CLL) and acute lymphocytic leukemia (ALL) are described.